Publications
337 publications
Sort by: Date / Relevance
GVS assessment of calcifediol (Hidroferol®)
Zorginstituut Nederland has completed its assessment whether calcifediol (Hidroferol®) is interchangeable with a medicine already ...
Package advice niraparib (Zejula®)
Zorginstituut Nederland has completed its assessment whether niraparib (Zejula®) can be included in the insured package. ...
GVS advice SGLT-2 inhibitors
Zorginstituut Nederland has completed its assessment the further conditions of SGLT-2 inhibitors canagliflozin (Invokana®), ...
GVS advice RZV (Shingrix®) for the prevention of herpes zoster and related post-herpetic neuralgia
Zorginstituut Nederland has completed its assessment whether the recombinant herpes zoster vaccine with adjuvant (RZV, Shingrix®) ...
GVS advice avatrombopag (Doptelet®) for the treatment of thrombocytopenia
Zorginstituut Nederland has completed its assessment whether avatrombopag (Doptelet®) is interchangeable with a product that is ...
GVS advice Vocabria® and Rekambys® for the treatment of HIV-1 infection
Zorginstituut Nederland has completed its assessment whether the products Rekambys® and Vocabria® can be included in the ...
Package advice isatuximab (Sarclisa®) for the treatment of multiple myeloma
Zorginstituut Nederland has completed its assessment whether isatuximab (Sarclisa®) in combination with carfilzomib and ...
GVS advice ivacaftor (Kalydeco®) extension of further conditions
Zorginstituut Nederland carried out a review to extend the further conditions for reimbursement of ivacaftor (Kalydeco®). The ...
GVS advice dapagliflozin (Forxiga®) extension of further condition
Zorginstituut Nederland has completed its assessment whether the further condition of dapagliflozin (Forxiga®) could be extended. ...
Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer
Zorginstituut Nederland has completed its assessment whether the fixed combined dose of pertuzumab and trastuzumab (Phesgo®) can ...